Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced financial results for the fourth quarter and full year
ended December 31, 2022, and provided an overview of recent
operational highlights.
“Our clinical activity is at a high point in the
Company’s history, and we believe it is setting the stage for a
year of significant accomplishments across an expanded portfolio of
novel pharmaceutical candidates designed to serve major unmet
medical needs,” said Seth Lederman, M.D., Chief Executive Officer
of Tonix.
“We are pleased with the progress of our current
Phase 3 program in fibromyalgia, and we are looking forward to the
results of a planned interim analysis due next quarter, followed by
topline results in the fourth quarter of this year. If successful,
we believe it will be the second and final adequate and
well-controlled efficacy trial required for filing a New Drug
Application (NDA) for approval by the U.S. Food and Drug
Administration (FDA)”, he added. “Moreover, we believe we have
satisfied all the other clinical and non-clinical requirements for
an NDA.”
Dr. Lederman added, “Patients and caregivers
alike report widespread dissatisfaction with the three currently
approved drugs for fibromyalgia – Lyrica®, Cymbalta®, and
Savella®, and generic pregabalin and duloxetine – switching back
and forth between them, and too often taking off-label products,
including addictive opiates. Fibromyalgia affects between six and
12 million adults in the U.S. according to the American Pain
Association, and there hasn’t been a new FDA drug approval in the
category in more than a dozen years.”
Dr Lederman continued, “Our recently expanded
late-stage clinical programs include four potentially pivotal Phase
2 trials. Two are currently enrolling, one in Long COVID and the
other in chronic migraine. The two others – one in depression and
the other in cocaine intoxication – are due to start enrolling. We
expect to initiate enrollment in the depression study by the end of
March, followed by the cocaine intoxication study in the second
quarter of this year.”
“In summary”, he concluded, “these programs,
together with several others in earlier development, represent a
diverse portfolio of programs with multiple opportunities for value
creation in 2023 and beyond.”
Recent Highlights—Key Product
Candidates*
Central Nervous System (CNS) Pipeline
TNX-102 SL (cyclobenzaprine HCl sublingual
tablet): small molecule for the management of fibromyalgia (FM)
- The first
50% of participants were randomized on December 19, 2022, in the
RESILIENT study, a double-blind, randomized, placebo-controlled,
potentially pivotal confirmatory Phase 3 study of TNX-102 SL for
the management of fibromyalgia. Results from a planned interim
analysis are expected in the second quarter of 2023, with topline
results expected in the fourth quarter of 2023. A positive topline
outcome, together with results from the previous positive Phase 3
RELIEF study, would support submission of an NDA.
TNX-102 SL for the treatment of
Fibromyalgia-Type Long COVID, also known as Post-Acute Sequelae of
COVID-19 (PASC)
- Enrollment
continues in the PREVAIL study, a potentially pivotal Phase 2 study
of TNX-102 SL for fibromyalgia-type Long COVID.
- During a February
2023 virtual event co-hosted by BIO and Solve M.E. titled, “Long
COVID: What Will it Take to Accelerate Therapeutic Progress?”, the
Company presented its analysis that the majority of Long COVID
patients present with a constellation of symptoms called
nociplastic pain that overlap with fibromyalgia, and Chronic
Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) and that
fibromyalgia-type Long COVID appears to be one of several chronic
overlapping pain conditions (COPCs) that are related by sharing the
neurological process called central sensitization.
TNX-1900 (intranasal potentiated oxytocin):
small peptide for migraine, craniofacial pain, insulin resistance
and related disorders, and obesity-associated binge eating
disorder
- In February 2023,
Tonix announced that enrollment began in the potentially pivotal
Phase 2 PREVENTION study of TNX-1900 for the prevention of migraine
headache in chronic migraineurs. The double-blind,
placebo-controlled study has a target enrollment of 300
participants at approximately 25 sites across the U.S. Results from
a planned interim analysis after the first 50% of enrolled patients
have completed the study are expected in the fourth quarter of
2023.
- In January 2023,
data from clinical and nonclinical studies were presented at the
16th Annual Headache Cooperative of the Pacific (HCOP) Winter
Conference by collaborator Professor David Yeomans. The oral
presentation titled, “Primary vs Secondary Sex Hormones and
Migraine,” includes research sponsored by and licensed by Tonix.
Preliminary results from a positron emission tomography (PET) study
in humans showed that intranasal application of a radioisotope of
magnesium-potentiated oxytocin is delivered to the trigeminal
ganglia which have known roles in migraine headaches. In addition,
preliminary results of data collected from isolated human
trigeminal ganglia neurons in vitro show co-expression of
oxytocin receptors and calcitonin gene-related peptide (CGRP),
which are believed to represent the first observation of oxytocin
receptors in human trigeminal ganglia. Furthermore, the
presentation highlights data which suggest a sex difference in
oxytocin potency.
- Tonix announced
data from an in vitro study describing the impact of oxytocin on
isolated human sensory neurons, presented by collaborator Professor
David Yeomans at Neuroscience 2022, the annual meeting of the
Society for Neuroscience. The poster, titled “In Vitro Impact
of Oxytocin on Human Sensory Neurons,” is the first to show that
oxytocin receptors are present on human sensory neurons and that
inflammation drives expression of oxytocin receptors on these
neurons. The results of this study are consistent with data from
animal models and provide support for the use of oxytocin for the
treatment of pain.
- An
investigator-initiated Phase 2 study of TNX-1900 in
obesity-associated binge eating disorder is expected to start
enrolling in the second quarter of 2023 directed by principal
investigator Professor Elizabeth Lawson at the Massachusetts
General Hospital, a teaching hospital of Harvard Medical
School.
TNX-601 ER (tianeptine hemioxalate
extended-release tablets): a once-daily orally-administered small
molecule for the treatment of major depressive disorder (MDD),
Posttraumatic Stress Disorder (PTSD), and neurocognitive
dysfunction associated with corticosteroid use.
- Enrollment is
expected to initiate in the first quarter of 2023 in the
potentially pivotal Phase 2 ‘UPLIFT’ Study for the treatment of
MDD. Results from planned interim analysis after the first 50% of
enrolled patients have completed the study are expected fourth
quarter 2023.
- TNX-601 ER
represents a novel approach to treating depression in the U.S.,
since the active ingredient tianeptine induces a neuroprotective
and resilient phenotype in both neurons and microglia under
conditions of stress. In contrast, antidepressants that are
marketed in the U.S. act by modulating neurotransmitter levels or
receptor binding in the synapse. The Phase 2 UPLIFT study is a
double-blind, randomized, multicenter, placebo-controlled study to
evaluate the efficacy and safety of TNX-601 ER taken orally
once-daily for 6 weeks to treat MDD. It is a parallel design study
with two arms, a TNX-601 ER 39.4 mg arm and a placebo arm. A total
of 300 participants will be randomized in a 1:1 ratio into the two
arms across approximately 30 U.S. sites, enrolling adult patients
18-65 years old with a DSM-5 diagnosis of depression and a duration
for the current major depressive episode (MDE) of at least 12
weeks. The primary efficacy endpoint is mean change from baseline
in the Montgomery-Åsberg Depression Rating Scale (MADRS) total
score at Week 6. Key secondary efficacy endpoints include the
Clinical Global Impression of Severity Scale (CGI-S) and the
Sheehan Disability Scale (SDS).
TNX-1300 (recombinant double mutant cocaine
esterase): biologic for life-threatening cocaine intoxication
- Tonix expects to
initiate a new, potentially pivotal, Phase 2 clinical study of
TNX-1300 for the treatment of cocaine intoxication in the second
quarter of 2023, pending agreement with the FDA on trial
design.
- As previously
mentioned, in 2022, Tonix received a Cooperative Agreement grant
from the National Institute on Drug Abuse (NIDA), part of the
National Institutes of Health (NIH), to support development of
TNX-1300.
- TNX-1300 has been
granted Breakthrough Therapy designation by the FDA.
Rare Disease Pipeline
TNX-2900 (intranasal potentiated oxytocin):
small peptide for the treatment of Prader-Willi syndrome (PWS)
- TNX-2900 has been
granted Orphan Drug designation from the FDA for the treatment of
PWS.
- As previously
mentioned, in 2022, Tonix delivered a presentation titled,
“TNX-2900 (Intranasal Oxytocin + Magnesium) in Development for the
Treatment of Hyperphagia in Adolescents and Young Adults with
Prader-Willi Syndrome” at the World Orphan Drug Congress USA.
Immunology Pipeline
TNX-1500 (anti-CD40L monoclonal antibody): third
generation anti-CD40L monoclonal antibody for prophylaxis of organ
transplant rejection and treatment of autoimmune disorders.
- A First-in-Human
Phase 1 study is expected to start in the second quarter of 2023 of
TNX-1500 for prophylaxis of organ rejection in adult patients
receiving a kidney transplant.
- In February 2023,
Tonix announced a research agreement with the University of
Maryland, Baltimore, to study and assess the role of TNX-1500 in
the prevention of heart xenograft rejection. The genetically
engineered pig donors will be provided by the Revivicor Division of
United Therapeutics Corporation. Preclinical xenotransplantation
studies are expected to support an IND application.
- Tonix announced a
research agreement with Boston Children’s Hospital to study
TNX-1500 for the prevention of graft-versus-host diseases (GvHD)
after hematopoietic stem cell transplantation (HCT) in animals. HCT
from unrelated donors is a component of the treatment protocol for
several hematologic malignancies, but GvHD complicates treatment
and limits the success of engraftment after HCT.
Infectious Disease Pipeline
TNX-801 (live horsepox virus vaccine for
percutaneous administration): vaccine to protect against smallpox
and mpox designed as a single-administration vaccine to elicit T
cell immunity
- A Phase 1 study in
is expected to start in the second half of 2023.
- Tonix presented a
development update from the Company’s TNX-801 vaccine program in an
oral presentation at the World Vaccine and Immunotherapy Congress
on December 1, 2022. The oral presentation titled, “Live Virus
Smallpox and Monkeypox Vaccine,” describes the history of live
virus vaccines and rationale for the development of the Company’s
Recombinant Pox Virus (RPV) platform, including TNX-801 to protect
against mpox and smallpox. Non-human primates vaccinated with
TNX-801 were fully protected with sterilizing immunity from a
lethal challenge with intra-tracheal monkeypox.
- A publication
describing the activity of TNX-801 to protect non-human primates
against a lethal challenge with intra-tracheal monkeypox was
published in the peer-reviewed journal, Viruses (Noyce RS, et al.
“Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801)
Vaccination Protects Macaques from Lethal Monkeypox Challenge.”
Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356. PMID:
36851570; PMCID: PMC9965234.)
*All of Tonix’s
product candidates are investigational new drugs or biologics and
none have been approved for any indication.
Recent Highlights—Corporate and
Other
- In February 2023,
Tonix announced the appointment of R. Newcomb Stillwell to its
Board of Directors, effective March 15, 2023. Mr. Stillwell is a
retired partner at Ropes & Gray LLP, an international law firm,
where he devoted approximately 38 years.
- In February 2023,
Tonix announced that it has exercised an option to obtain an
exclusive license from Columbia University for the development of a
portfolio of fully human (TNX-3600) and murine (TNX-4100)
monoclonal antibodies for the treatment or prophylaxis of
SARS-CoV-2 infection. The licensed monoclonal antibodies were
developed as part of a research collaboration and option agreement
between Tonix and Columbia University, originally announced in
2020.
- In February 2023,
Tonix announced the acquisition of a preclinical portfolio of
next-generation antiviral technology assets from Healion Bio, Inc.
(Healion). Healion’s drug portfolio includes a class of
broad-spectrum small molecule oral antiviral drug candidates
including TNX-3900, formerly known as HB-121, which are cathepsin
protease inhibitors, some of which have activity in
vitro against SARS-CoV-2.
- On January 26,
2023, data from Tonix’s research collaboration with The University
of Alberta were presented by Tom Hobman, Ph.D., Professor of Cell
Biology, University of Alberta, during a presentation at the 2nd
Wnt/β-catenin Targeted Drug Development Conference. The oral
presentation titled, “Targeting the Wnt/β-catenin pathway as a
broad-spectrum antiviral strategy,” includes research sponsored by
Tonix Pharmaceuticals focused on the development and testing of
Wnt/β-catenin signaling pathway inhibitors as broad-spectrum
antivirals against SARS-CoV-2 and other emerging viruses.
- In January 2023,
Tonix announced the publication of a paper entitled, “Development
of a rapid image-based high-content imaging screening assay to
evaluate therapeutic antibodies against the monkeypox virus,” in
the journal Antiviral Research. The publication describes the
development and optimization of two high-content image-based assays
that were employed to screen for potential therapeutic antibodies
against the monkeypox virus using surrogate poxviruses such as
vaccinia virus. The article highlights Tonix’s TNX-3400 platform,
which includes antibodies to potentially prevent or treat mpox and
smallpox. These data represent the first wave of research and
development conducted at the Company’s Infectious Disease R&D
Center (RDC) in Frederick, Md. (Kota KP, et al., “Development of a
rapid image-based high-content imaging screening assay to evaluate
therapeutic antibodies against the monkeypox virus.” Antiviral Res.
2023 Feb;210:105513. doi: 10.1016/j.antiviral.2022.105513. Epub
2022 Dec 30. PMID: 36592670; PMCID: PMC9803393.)
- In January 2023,
Tonix announced the appointment of Zeil Rosenberg, M.D., M.P.H. as
its new Executive Vice President, Medical.
- Tonix announced
data from its fully human anti-SARS-CoV-2 monoclonal antibody
platform in an oral presentation at the World Antiviral Congress
2022. The presentation titled, “Platform for Generating Fully
Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal
Antibodies” highlights the need for a broad array of
monoclonal antibodies which can be scaled up quickly and
potentially combined with other monoclonal antibodies to treat or
prevent COVID-19. The platform is part of a broader research
collaboration and option agreement with scientists at Columbia
University designed to fill in important gaps in understanding the
detailed immune responses to COVID-19, and to provide a foundation
upon which to target vaccines and therapeutics to appropriate
individuals by precision medicine.
- In December 2022,
Tonix announced that it has obtained an exclusive license from
Curia Global, Inc., a leading contract research, development and
manufacturing organization, for the development of three humanized
murine monoclonal antibodies for the treatment or prophylaxis of
SARS-CoV-2 infection, the cause of COVID-19. Immunocompromised
individuals, including organ transplant recipients, are at
increased risk of severe COVID-19 and poor clinical outcomes.
SARS-CoV-2 has mutated to evade the existing FDA Emergency Use
Authorization (EUA)-approved therapeutic monoclonal
antibodies.
Recent
Highlights—Financial
As of December 31, 2022, Tonix had $120.2 million of cash and
cash equivalents, compared to $178.7 million as of December 31,
2021. Net proceeds from financing activities were approximately
$87.8 million for full year 2022, compared to $212.5 million for
the full year 2021.
Since January 1, 2023, the Company repurchased 15,700,269 shares
of common stock under a $12.5 million share purchase program at
prices ranging from $0.44 to $1.38 for a gross aggregate cost of
approximately $12.5 million.
In January 2023, the Board of Directors approved a new $12.5
million share repurchase program. Since January 1, 2023,
the Company repurchased 1,000,000 shares of common stock under this
share repurchase program at $1.14 for a gross aggregate cost of
$1.1 million.
Cash used in operations was approximately $98.1
million for the full year 2022, compared to $75.6 million for the
full year 2021. The increase in cash outlays was primarily due to
an increase in research and development (R&D) and general and
administrative (G&A) activities, described below.
Cash used by investing activities for the years
ended December 31, 2022, and 2021 was approximately $48.1 million
and $35.3 million, respectively, related to the purchase of
property and equipment.
Fourth Quarter 2022 Financial Results
R&D expenses for the fourth quarter 2022
were $24.7 million, compared to $22.3 million for the same period
in 2021. The increase is predominately due to increased
employee-related, facility and laboratory expenses. We expect
R&D expenses to increase during 2023 as we move our clinical
development programs forward and invests in our development
pipeline.
G&A expenses for the fourth quarter 2022
were $8.1 million, compared to $7.3 million for the same period in
2021. The increase is primarily due to increased employee-related
and financial reporting expenses.
Net loss available to common stockholders was
$34.1 million, or $0.56 per share, basic and diluted, for the
fourth quarter 2022, compared to net loss of $29.6 million, or
$2.08 per share, basic and diluted, for the same period in 2021.
The basic and diluted weighted average common shares outstanding
for the fourth quarter 2022 was 61,379,692 compared to 14,230,897
shares for the same period in 2021.
Full Year 2022 Financial Results
R&D expenses for the full year 2022 were
$81.9 million, compared to $68.8 million for the same period in
2021. The increase is predominately due to increased
employee-related, facility and laboratory expenses. We expect
R&D expenses to increase during 2023 as we move our clinical
development programs forward and invest in our development
pipeline.
G&A expenses for the full year 2022 were
$30.2 million, compared to $23.5 million for the same period in
2021. The increase is primarily due to increased employee-related
and financial reporting expenses.
Net loss available to common stockholders was
$116.9 million, or $3.27 per share, basic and diluted, for the full
year 2022, compared to net loss of $92.3 million, or $8.10 per
share, basic and diluted, for the same period in 2021. The basic
and diluted weighted average common shares outstanding for full
year 2022 was 35,739,057 compared to 11,387,308 shares for the same
period in 2021.
Tonix Pharmaceuticals Holding
Corp.*
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix’s portfolio is composed of central nervous system
(CNS), rare disease, immunology and infectious disease product
candidates. Tonix’s CNS portfolio includes both small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine
HCl sublingual tablet), is in mid-Phase 3 development for the
management of fibromyalgia with a new Phase 3 study launched in the
second quarter of 2022 and interim data expected in the second
quarter of 2023. TNX-102 SL is also being developed to treat
fibromyalgia-type Long COVID, a chronic post-acute COVID-19
condition. Tonix initiated a Phase 2 study in Long COVID in the
third quarter of 2022. TNX-1900 (intranasal potentiated oxytocin),
a small molecule in development for chronic migraine, is being
studied in a potential pivotal Phase 2 study that initiated
enrollment in the first quarter of 2023 and for which interim data
is expected in the fourth quarter of 2023. TNX-601 ER (tianeptine
hemioxalate extended-release tablets) is a once-daily formulation
of tianeptine being developed as a potential treatment for major
depressive disorder (MDD) with a Phase 2 study expected to be
initiated in the first quarter of 2023. TNX-1300 (cocaine esterase)
is a biologic designed to treat cocaine intoxication and has been
granted Breakthrough Therapy designation by the FDA. A Phase 2
study of TNX-1300 is expected to be initiated in the second quarter
of 2023. Tonix’s rare disease portfolio includes TNX-2900
(intranasal potentiated oxytocin) for the treatment of Prader-Willi
syndrome. TNX-2900 has been granted Orphan Drug designation by the
FDA. Tonix’s immunology portfolio includes biologics to address
organ transplant rejection, autoimmunity and cancer, including
TNX-1500, which is a humanized monoclonal antibody targeting
CD40-ligand (CD40L or CD154) being developed for the prevention of
allograft and xenograft rejection and for the treatment of
autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be
initiated in the second quarter of 2023. Tonix’s infectious disease
pipeline includes a vaccine in development to prevent smallpox and
mpox, TNX-801; a next-generation vaccine to prevent COVID-19,
TNX-1850; a platform to make fully human and murine monoclonal
antibodies to treat COVID-19, TNX-3600 and TNX-4100, respectively;
and humanized anti-SARS-CoV-2 monoclonal antibodies, TNX-3800; and
a class of broad-spectrum small molecule oral antivirals, TNX-3900.
TNX-801, Tonix’s vaccine in development to prevent smallpox and
mpox, also serves as the live virus vaccine platform or recombinant
pox vaccine (RPV) platform for other infectious diseases. A Phase 1
study of TNX-801 is expected to be initiated in the second half of
2023.
*All of Tonix’s product candidates are
investigational new drugs or biologics and have not been approved
for any indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; delays and uncertainties caused
by the global COVID-19 pandemic and social and economic unrest;
risks related to the timing and progress of clinical development of
our product candidates; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and
substantial competition. As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report as filed with the Securities and
Exchange Commission (the “SEC”) and periodic reports filed with the
SEC on or after the date thereof. All of Tonix's forward-looking
statements are expressly qualified by all such risk factors and
other cautionary statements. The information set forth herein
speaks only as of the date thereof.
TONIX PHARMACEUTICALS HOLDING
CORP. CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS(In Thousands, Except Share and Per
Share Amounts)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year EndedDecember 31, |
|
|
Three Months EndedDecember
31, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
COSTS
AND EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
81,876 |
|
|
$ |
68,838 |
|
|
$ |
24,674 |
|
|
$ |
22,296 |
|
General
and administrative |
|
|
30,215 |
|
|
|
23,474 |
|
|
|
8,054 |
|
|
|
7,183 |
|
|
|
|
112,091 |
|
|
|
92,312 |
|
|
|
32,728 |
|
|
|
29,479 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(112,091 |
) |
|
|
(92,312 |
) |
|
|
(32,728 |
) |
|
|
(29,479 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income, net |
|
|
1,873 |
|
|
|
25 |
|
|
|
1,048 |
|
|
|
(74 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss |
|
|
(110,218 |
) |
|
|
(92,287 |
) |
|
|
(31,680 |
) |
|
|
(29,553 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock deemed dividend |
|
|
6,659 |
|
|
|
— |
|
|
|
2,404 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
available to common stockholders |
|
$ |
(116,877 |
) |
|
$ |
(92,287 |
) |
|
$ |
(34,084 |
) |
|
$ |
(29,553 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
per common share, basic and diluted |
|
$ |
(3.27 |
) |
|
$ |
(8.10 |
) |
|
$ |
(0.56 |
) |
|
$ |
(2.08 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average common shares outstanding, basic and diluted |
|
|
35,739,057 |
|
|
|
11,387,308 |
|
|
|
61,379,692 |
|
|
|
14,230,897 |
|
TONIX PHARMACEUTICALS HOLDING
CORP.CONDENSED CONSOLIDATED BALANCE
SHEETS (In
Thousands)(Unaudited)
|
December 31, 20221 |
|
|
December 31, 20211 |
Assets |
|
|
Cash and cash equivalents |
$ |
120,229 |
|
$ |
178,660 |
Prepaid expenses and other |
|
10,548 |
|
|
10,389 |
Total
current assets |
|
130,777 |
|
|
189,049 |
Other
non-current assets |
|
94,913 |
|
|
51 ,851 |
Total
assets |
$ |
225,690 |
|
$ |
240,900 |
|
|
|
Liabilities and stockholders' equity |
|
|
Total
liabilities |
$ |
18,508 |
|
$ |
22,183 |
Stockholders' equity |
|
207,182 |
|
|
218,717 |
Total
liabilities and stockholders' equity |
$ |
225,690 |
|
$ |
240,900 |
1The condensed consolidated balance sheet for the years ended
December 31, 2022 and December 31, 2021 has been derived from the
audited financial statements but do not include all of the
information and footnotes required by accounting principles
generally accepted in the United States for complete financial
statements.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182
Olipriya Das, Ph.D. (media)Russo
PartnersOlipriya.Das@russopartnersllc.com (646) 942-5588
Peter Vozzo (investors)ICR
Westwickepeter.vozzo@westwicke.com(443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to Jun 2023
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Jun 2022 to Jun 2023